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Abstract
Bacground/Aim. Mucosa-associated lymphoid tissue
(MALT) lymphoma accounts for 5–17% non-Hodgkin
lymphomas (NHL). The molecular pathogenesis of MALT
lymphomas is not well-established. The aim of this study
was to evaluate immunohistochemically determined nu-
clear coexpression of BCL10 and NF-kappaB (NF-ƪB) in
tumor cells of gastric MALT lymphoma and its impact on
the patogenesis and outcome of the disease. Methods.
Medical records of 35 patients with newly diagnosed gas-
tric MALT lymphoma were analyzed and biopsy speci-
mens were immunostained for BCL10 and NF-kB expres-
sion (p65 subunit). Results. The median age of 35 pa-
tients diagnosed with gastric MALT lymphoma was 63.5
years (male/female = 21/14). Symptoms were present in
23/35 (65.7%) patients with the weight loss as the most
common symptom. Gastric MALT lymphomas were usu-
ally localized in the stomach corpus and corpus and an-
trum (45.7% and 31.2%, respectively). H. pylori infection
was confirmed in 20 out of 30 (66.7%) patients. Treatment
options were as follows: immunochemotherapy in 10
(28.5%) patients, surgery in 9 (25.8%) patients, combined
surgery and chemotherapy in 14 (40%) patients and sup-
portive measures in 2 (5.7%) patients. Complete remission
was achieved in 13 (37.1%) patients and partial remission
in two (5.7%) patients. Sixteen (45.7%)  patients had dis-
ease progression (p < 0.001). Cytoplasmatic expression of
BCL10 in tumor cells was detected in 19 (54.3%) speci-
mens. Nuclear expression was detected in no specimen.
Cytoplasmic expression of NF-  ƪB was present in 22
(65.7%) specimens, but nuclear expression was not de-
tected in any specimens. Conclusion. Nuclear expressions
(activation) of NF-ƪB p65 subunit and BCL10 were not
detected in specimens of gastric MALT lymphoma. The
correlation of nuclear coexpression of BCL10 and NF-ƪB
in gastric MALT lymphoma was not established. These re-
sults indicate that other mechanisms and signal pathways
are active in lymphogenesis of gastric MALT lymphoma,
as that apoptotic inhibition is not the main, nor the only
mechanism in tumorogenesis.
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Apstrakt
Uvod/Cilj.  Limfomi limfnog tkiva pridruženog mukozi
(MALT)  ÿine 5–17% svih non-Hodgkin limfoma (NHL).
Molekularna patogeneza MALT limfoma nije razjašnjena.
Cilj ove studije bio je da se imunohistohemijski utvrdi prisu-
stvo nuklearne koekspresije BCL10 i NF-kappaB (NF-ƪB) u
tumorskim ýelijama želudaÿnog MALT limfoma kao i nji-
hov uticaj na patogenezu i ishod bolesti. Metode. Analizi-
rani su kliniÿki podaci iz istorija bolesti 35 bolesnika sa no-
vodijagnostikovanim želudaÿnim MALT limfomom i uzorci
tkiva biopsije želuca bojeni su imunohistohemijskom meto-
dom na ekspresiju BCL10 i NF-ƪB.  Rezultati.  Proseÿna
starost kod 35 bolesnika sa dijagnozom želudaÿnog MALT
limfoma iznosila je 63,5 godina (muškarci/žene = 21/14).
Simptomi su bili prisutni kod 23/35 (65,7%) bolesnika sa
gubitkom težine kao najÿešýim simptomom. Želudaÿni
MALT limfom bio je najÿešýe lokalizovan u korpusu i kor-
pusu i antrumu (45,7% i 31,2%). Infekcija H. pylori bila je
potvrĀena kod 20 od 30 (66,7%) bolesnika. Bolesnici su le-
ÿeni imunohemioterapijom (10 bolesnika, 28,5%), hirurški
(9 bolesnika, 25,8%), kombinacijom hirurgije i hemioterapije
(14 bolesnika, 40%) i suportivno (2 bolesnika, 5,7%). Kom-
pletna remisija bila je postignuta kod 13 (37,1%) bolesnika, a
parcijalna remisija kod dva (5,7%) bolesnika. Kod 16
(45,7%) bolesnika došlo je do progresije bolesti (p < 0,001).Volumen 71, Broj 11 VOJNOSANITETSKI PREGLED Strana 1041
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Citoplazmatska ekspresija BCL10 bila je naĀena kod 19
(54,3%) tumorskih ýelija. Nuklearna ekspresija nije uoÿena
ni u jednom uzorku. Citoplazmatska ekspresija NF-ƪB bila
je prisutna u 22 (65,7%) uzorka, ali nuklearna ekspresija nije
potvrĀena ni u jednom uzorku. Zakljuÿak. Nuklearna eks-
presija (aktivacija) p65 subjedinice NF-ƪB puta i BCL10 nije
otkrivena u uzorcima želudaÿnog MALT limfoma. Korela-
cija nuklearne koekspresije BCL10 i NF-ƪB u tumorskim
ýelijama želudaÿnog MALT limfoma nije utvrĀena. Ovi re-
zultati ukazuju da su neki drugi mehanizmi i signalni putevi
aktivni u limfogenezi želudaÿnog MALT limfoma i da inhibi-
cija apoptoze nije glavni i jedini mehanizam tumorogeneze.
Kljuÿne reÿi:
limfom, malt; želudac, neoplazme; imunohistohemija;
geni, ekspresija; signali, transdukcija.
Introduction
Mucosa-assciated lymphoid tissue (MALT) lymphomas
are defined as extranodal B-cell lymphomas of marginal
zone that originate from lymphatic tissue associated with
mucosal and glandular epithelium 
1. MALT lymphomas ac-
count for 5–17% of non-Hodgkin lymphomas (NHL) 
2. They
can  occur in any organ, most commonly in the stomach,
lungs, salivary glands and thyroid gland. MALT lymphoma
of the stomach account for about 40% of all primary gastric
NHL 
3. They predominantly occur between 50 and 60 years
of age and there is no gender preponderance 
4. Morphologi-
cally, they are present as multifocal gastric lesions usually
accompanied with gastrointestinal symptoms. At presenta-
tion, the disease is localized and usually have indolent course
with histological transformation to large-cell lymphoma in
10% of cases later on 
2. The 5-year survival is between 95%
and 85% 
5. Association with H. pylori infection in 90% of
gastric MALT lymphomas was proven 
6, 7. It is assumed that
malignant transformation of B lymphocytes is caused by
chronic antigenic stimulation with Helicobacter infection. As
a result of direct and indirect (T-cells specific for H. pylori)
antigen stimulation B cells proliferate and can, at times, un-
dergo a neoplastic transformation following the acquisition
of genetic abnormalities 
3. In more than half of patients with
MALT lymphomas structural cytogenetic abnormalities with
translocation t (11; 18), t (1; 14), t (14; 18) are described,
while the most common numeric cytogenetic abnormality is
trisomy 3. These translocations result in the generation of the
novel fusion proteins, aberrant nuclear BCL10 expression
and activation of the nuclear factor kappaB (NF-țB) patha-
way. NF-țB induction appears to drive antigen independent
growth of lymphoma cells.
BCL10 activates NF-țB transcription factor and in-
hibits apoptosis. Binding beetween BCL10 and MALT1 is
crucial for the oligomerisation and self-activation of
MALT1, which leads to NF-țB activation 
3. Physiologi-
caly, BCL10 is found to be abundant in the cytoplasm of B
lymphocytes in germinative center and moderately ex-
pressed in the cytoplasm of B lymphocytes of the marginal
zone of follicules. An ectopic, nuclear localization of
BCL10 was observed in some cells of gastric MALT lym-
phoma. The degree of BCL10 expression correlates to the
type of cytogenetic abnormality. In gastric MALT lym-
phoma with t (11; 18) nuclear BCL10 expression is usually
moderate; in t (1; 14) nuclear expression of BCL10 is
prominent; while t (14; 18) is characterized with cytoplas-
matic expression of BCL10 
8.
NF-țB is a dimeric transcription factor that belongs to
the family of Rel (reticuloendotheliosis) proteins, composed
of five proteins (p50, p52, p65, c-Rel, RelB). NF-țB is pre-
dominantly located in the cytoplasm of the cells as inactive
cytoplasmic complex with the inhibitor țB (IțB) 
9. After
phosphorylation of IțB, NF-țB is released from the complex
NF-țB/IțB and goes into the nucleus, where it controls the
transcription of various genes that play a key role in the
regulation of many cellular processes such as inflammation,
proliferation, immunity, angiogenesis and apoptosis 
10. NF-
țB signaling pathway is activated after stimulation of cell
proinflammatory cytokines, mitogens, growth factors, anti-
gens, oxidative stress triggers and intercellular contact and
plays an important role in the development of various tu-
mors. Activity of NF-țB pathway in tumor cells is assesed
on the basis of the nuclear localization of its subunits (com-
monly p50, p52 and p65).
The aim of this study was to determine nuclear coex-
pression of BCL10 and NF-țB in tumor cells of gastric
MALT lymphoma and its impact on the patogenesis and out-
come of the disease.
Methods
We analyzed medical records of 35 patients with newly
diagnosed gastric MALT lymphoma between January 2001
and July 2007. The study was conducted in retrospective-
prospective manner. The patients were followed until March
2010. The study included 35 patients: 21 male and 14 fe-
male. The median age was 63.5 years (range 35–77 years).
There were 17 (48.6%) patients younger than 65 years and
18 (51.4%) patients older than 65 years. Clinical characteris-
tics of patients were sumarized in Table 1. Histopathologic
diagnosis was made according to the Revised European
American Lymphoma/World Health Organization
(REAL/WHO) classification. The presence of H. pylori in
gastric mucosa was determined by standard Geimsa staining
of biopsy sample.
The immunoexpression of BCL10 and NF-țB was de-
termined in biopsy tissue samples of gastric MALT lym-
phomas by standard avidin-biotin-streptavidin immunohisto-
chemical method. The expression of NF-țB in tumor cells of
gastric MALT lymphoma was determined by using mono-
clonal antibody p65 NF-țB (Thermo Vision Corporation;
dilution 1 : 50). The expression of BCL10 was determined
by using monoclonal antibody BCL10 (DAKO; dilution
1 : 25). Paraffin embedded normal lymphoid tissue was used
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BCL10 immunoreactivity was interpreted as positive or
negative, as well as cytoplasmic, cytoplasmic and nuclear, or
nuclear. Staining intensity was graded as weak, moderate or
strong. Approximate cutoff of  20% was used to classify
tumors as having weak and strong expression. NF-țB p65
immunoreactivity was categorized as cytoplasmic (inactive)
or nuclear staining (active). Positive staining patterns were
claimed if protein expression was detected in more than 10%
of the cells.
A treatment response was evaluated a month after the
therapy completition. Data were summarized by frequency
and percentage for categorical variables. For continuous
variables, the medians and ranges were computed. Statistical
tests were 2-sided at the 5% level of significance. Univariate
analysis using the nonparametric Wilcoxon rank-sum test or
the Kruskall-Wallis rank-sum test when appropriate were
performed to investigate the association between continuous
variables and categorical variables. Statistical analyses were
performed by using statistical package SPSS (version 11.5
for Windows).
Results
The most common symptom at presentation was epigas-
tric pain registered in 25 (71.4%) patients (p < 0.001) (Table
1). Epigastric pain associated with gastrointestinal bleeding
was registered in additional 8 (22.9%) patients. B symptoms
were present in 23 (65.7%) patients with weight loss as the
most common (p < 0.063). MALT lymphoma was usually lo-
calized in the gastric corpus (16 or 45.7% patients). The cor-
pus and antrum were often simultaneously affected (11 or
31.2% patients; p < 0.001). Tumor lesions usually appeared as
macroscopic ulcerations (24 or 68% patients), diffuse infiltra-
tive growth was seen in 8 (22.9%) patients whilst polypoid
growth pattern was seen in only 3 (8.6%; p < 0.0001) patients.
Giemsa staining confirmed H. pylori infection in 20 out of 30
tested patients (histochemical analysis was not done in 5
specimens due to technical reasons) (Table 1). The most of the
patients (14 or 40%) were in clinical stage IV according to the
Lugano staging system while 8 (22.9%) were in clinical stage I
and 13 (37.1%) in clinical stage II at the time of presentation.
The most of the patients (21 or 60%) had disseminated disease
at presentation. Disseminated disease was defined as the pres-
ence of multifocal lesions or as nonmucosal organs infiltration
(distant lymph node, bone marrow, spleen, liver, pleura) to-
gether with the presence of the disease in one MALT tissue.
The patients were treated as follows: immunochemotherapy in
10 (28.5%) patients, surgery in 9 (25.8%) patients, combined
surgery and chemotherapy in 14 (40%) patients. H. pylory
eradication in combination with chemotherapy was performed
in 2 (5.7%) patients and supportive measures in 2 (5.7%) pa-
tients. Complete remission was achieved in 13 (37.1%) of the
patients and partial remission in two (5.7%) patients. Sexteen
patients had disease progression (45.7%; p < 0.001).  There
was no reliable data on treatment outcome in 4 patients (un-
complete medical records). The most of the patients (8 out of
13) achieved a complete remission when treated with a com-
bined modality (surgery and chemotherapy). There was no
significant difference in treatment modality among patients
with progressive disease (p > 0.05).
Table 1
Clinical features of patients with gastric MALT lymphoma (Ȥ
2-test)
Patients caracteristics n % p
Age (years)
< 65 17 48.6
> 65 18 51.4
0.866
Gender
male 21 60
female 14 40
0.237
B symptoms
yes 12 33.3
no 23 65.7
0.063
Karnofsky index
> 60% 30 85.7
< 60% 5 14.3
0.0001
Disease symptoms
epigastric pain 25 71.4
epigastric pain + melena 8 22.9
peritoneal effusion 1 2.9
without symtoms 1 2.9
0.001
Disease dissemination
yes 21 60
no 14 40
0.237
Macroscopic tumor pattern
ulceration 24 68.6
polypus 3 8.6
diffuse-infiltrative pattern 8 22.9
0.0001
H. pylori infection
positive 20 57.4
negative 10 28.1
not done 5 14.3
0.007
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The results of immunoexpression in tumor specimens of
gastric MALT lymphoma are showed in Table 2.
BCL10 cytoplasmic expression was detected in 19
(54.3%) biopsy specimens: 15 had moderate, three low and
one prominent cytoplasmic positivity (Table 2). In 16
(45.7%) specimens, BCL10 expression was not found in the
nucleus, nor in the cytoplasm. BCL10 nuclear expression
was found in no specimen.
NF-țB cytoplasmatic expression was found in 22
(65.7%) patients (Tables 1 and 2). In four (11%) patients
cytoplasmic and nuclear expressions of NF-țB were posi-
tive, but nuclear expression was present in less than 10% of
cells, which is not considered significant in terms of activity
of this transcription factor. In other words, cytoplasmic ac-
tivity means the presence, but not the activity of NF-țB tran-
scriptional factor.
Since nuclear expression of BCL10 or NF-țB was not
found it could be concluded that some other mechanisms and
signal pathways are active in lymphogenesis of gastric
MALT lymphoma. So, the found cytoplasmic expression
was not correlated to clinical patients features.
Discussion
The patients in this study diagnosed with gastric MALT
lymphoma were mostly older than 50 years, with good per-
formance score as alredy reported 
5. In contrast to recent ten-
dencies (in developed health systems) to diagnose the disease
at an early stage, gastric lymphoma in our patients was usu-
ally diagnosed at an advanced stage. Also, according to lit-
erature data, gastric MALT lymphoma is most frequently lo-
calized in the gastric antrum and presented as multiple ul-
cerations, but in our patients lymphoma was localized in the
corpus and presented mostly as ulcerative lesions. Therapeu-
tic approach in patients with gastric MALT lymphoma is
controversial and not standardized. Our patients were first
seen by the surgeon, since the main symptom at presentation
was abdominal pain. Therefore the most common therapeutic
approach was surgery and the reason while eradication ther-
apy for H. pylory was not common.
The molecular pathogenesis of MALT lymphomas
arising in the gaster is not well-established, but it is known
that malignant transformation disrupt the cell signaling
pathway and allows its autonomous behavior. As shown by
others, at least three of the chromosomal translocations were
identified in MALT lymphomas [t (11; 18), t (14; 18), and t
(1; 14)] and result in deregulation of BCL10 and downstream
activation NF-țB pathway 
11, 12.
We used BCL10 immunostaining to indirectly assess for
MALT lymphoma-associated translocations since BCL10 im-
munostaining has been reported to show characteristic expres-
sion patterns that correlate with the presence of specific trans-
locations. In MALT lymphomas carrying the t (1; 14), BCL10
is predominantly and strongly expressed in the tumor cell nu-
clei. In MALT lymphomas with the t (11; 18) or t (14; 18),
BCL10 is moderately expressed in the nucleus or strongly ex-
pressed in the cytoplasm of tumor cells, respectively 
8, 12, 13.
However, nuclear expression of BCL10 can be found in up to
50% MALT lymphomasa without specific translocation 
14, 15.
Therefore, the significance of nuclear expression of BCL10 in
lymphogenesis stil remains unexplained.
In 16 (45.7%) samples of gastric MALT lymphoma in
this study, immunohistochemical BCL10 staining was not
detected either in cytoplasm or nucleus, suggesting that it is
not the central mechanism responsible for lymphogenesis.
Beside ectopic nuclear localization of BCL10 an altered
function of mutant forms of BCL10 protein could be also re-
sponsible for lymphogenesis. However, mutated forms of
BCL10 protein are difficult to detect using immunohisto-
chemical metod 
16. Thus, although BCL10 immunostaining
can be used as an initial screen for the t (11; 18) in MALT
lymphomas, the presence of BCL10 nuclear expression
should not be used as a surrogate for the presence of the t
(11; 18). Nuclear expression of BCL10 has prognostic sig-
nificance since it is a common feature of disseminated forms
of gastric MALT lymphoma 
15, 17. Disseminated forms are
associated with structural cytogenetic aberrations as t (1; 14)
and t (11; 18) and usually without the effect of H. pylori
eradication therapy) 
8, 18. However, 60% in our study group
presented with disseminated form of the disease, but none of
the patients had nuclear expression of BCL10.
Immunohistochemical
  staining was also performed to
evaluate the expression of p65 subunits of NF-țB. In many
different tumor types, and in some gastric and ocular adnexal
MALT lymphomas, the evidence of NF-țB activation has
been shown in a subset of cases 
19. As the p65 subunit is in-
volved in many activated forms of NF-țB, immunohisto-
chemical detection of nuclear p65 staining is used as evi-
dence of NF-țB activation 
20. In all the studied cases, the
staining pattern was only cytoplasmic, and therefore nega-
tive, suggesting that NF-țB is inactive. These results further
suggest that MALT lymphoma-associated translocations that
are known to activate NF-țB were absent or rare in our
studied cases of gastric MALT lymphomas. However, we
cannot exclude the possibility that NF-țB activation still ex-
ist in these MALT lymphomas cases, involving other mem-
bers of Rel proteins family (p50, p 52).
In this study, in 35 MALT lymphoma specimens, nuclear
coexpression of BCL10 and NF-țB in tumor cells was not
found. It is interesting to note that Talwalker et al. 
20 found
Table 2
Immunoexpression in tumor specimens of gastric MALT lymphoma
BCL10 NF-țB Cytoplastatic staining (%) (%)
Positive 54.3 65.7
Negative 45.7 34.3
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BCL10 positivity in some cases of breast MALT lymphomas
despite NF-țB negativity in all of them, but none of the cases
had MALT1 gene rearrangements confirmed by fluoreseence
in situ hybridization (FISH). This suggests that BCL10 immu-
nostaining overestimates the frequency of MALT1 gene rear-
rangements 
21. Moreover, Sagaert et al. 
22, 23 studied 77 patients
with MALT lymphoma and found translocations involving
MALT1 and BCL10 gene in only 1% of patients, concluding
that other structural or numerical chromosome disorders may
be responsible for tumorigenesis and lymphogenesis. Similar
conclusions can be widrawn from our study ie that lympho-
genesis pathway in our cases should be explained other than
by activation of BCL10 and NF-țB.
Conclusion
Nuclear expression of NF-țB p65 subunit and BCL10
were not detected in studied specimens of gastric MALT
lymphoma. These results indicate that other mechanisms and
signal pathways are active in lymphogenesis of gastric
MALT lymphoma, and that apoptotic inhibition is not the
main, nor the only mechanism in tumorogenesis.
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